Inivata, in Collaboration with World-Leading Academic Centers, to Present Promising New Clinical Data on the Utility of the InVision™ ctDNA Platform across Multiple Tumor Types at ASCO 2017 Annual Meeting

2017, News

Collaborative projects with leading cancer research centers highlight progress in development of Inivata’s InVision ctDNA liquid biopsy platform

Inivata, a global clinical cancer genomics monitoring company employing a revolutionary approach to circulating tumor DNA (‘ctDNA’) analysis to improve personalized healthcare in oncology, today announces that six posters will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held from June 2-6 2017 at McCormick Place, Chicago, Illinois, USA.

The posters will present new clinical data from collaborations with prestigious cancer centers on the use of Inivata’s highly sensitive InVision ctDNA liquid biopsy platform in the analysis of multiple tumor types:

Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA
Inivata and University of Chicago Pritzker School of Medicine
Abstract No.: 4124
Session Title: Gastrointestinal (Noncolorectal) Cancer
Presentation Time: Saturday 3 June, 08:00 – 11:30
Location: Hall A, Poster Board #116

Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)
Inivata and National Cancer Institute of Canada
Abstract No.: 9024
Session Title: Lung Cancer – Non-Small Cell Metastatic
Presentation Time: Saturday 3 June, 08:00 – 11:30
Location: Hall A, Poster Board #350

Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib
Inivata and Dana Farber Cancer Institute
Abstract No.: 11529
Session Title: Tumor Biology
Presentation Time: Saturday 3 June, 13:15 – 16:45
Location: Hall A, Poster Board #229

Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC)
Inivata and Gustave Roussy
Abstract No.: 11540
Session Title: Tumor Biology
Presentation Time: Saturday 3 June, 13:15 – 16:45
Location: Hall A, Poster Board #240

Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting
Inivata and Gustave Roussy
Abstract No.: 11532
Session Title: Tumor Biology
Presentation Time: Saturday 3 June, 13:15 – 16:45
Location: Hall A, Poster Board #232

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer
Inivata and The Institute of Cancer Research
Abstract No.: 1015
Session Title: Breast Cancer – Metastatic
Presentation Time: Sunday 4 June, 08:00 – 11:30, 16:45 – 18:00
Location: Hall A, Poster Board #7

The abstracts are now available on the ASCO meeting website, www.asco.org. The data presented will be available both on the ASCO and Inivata websites after the conference.

Clive Morris, Chief Medical Officer of Inivata, said:

“We are delighted to present these six high quality abstracts at the ASCO Annual Meeting. These publications, in collaboration with a number of world-renowned cancer research centers, add to the growing body of evidence supporting the potential clinical utility of our InVision platform across a range of tumor types.”

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

 

Media Contacts

Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson (UK)
Catherine London (US)

inivata@consilium-comms.com +44 (0)20 3709 5700

Inivata
Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News